Table I.
Association between BRAF V600E or TERT promoter mutations and clinicopathological characteristics in patients with papillary thyroid carcinoma.
| BRAF V600E | TERT promoter mutation | |||||||
|---|---|---|---|---|---|---|---|---|
| Clinicopathological features | Mutated, n=169 | Wild type, n=36 | OR (95% CI) | P-value | Mutated, n=8 | Wild type, n=197 | OR (95% CI) | P-value |
| Sex | ||||||||
| Female | 133 | 28 | 0.947 | 0.903 | 5 | 156 | 2.283 | 0.373 |
| Male | 36 | 8 | (0.398-2.256) | 3 | 41 | (0.524-9.950) | ||
| Age at diagnosis (years) | ||||||||
| ≤45 | 90 | 16 | 0.702 | 0.337 | 1 | 105 | 7.989 | 0.030a |
| >45 | 79 | 20 | (0.341-1.448) | 7 | 92 | (1.001-66.154) | ||
| Tumor size (mm) | ||||||||
| ≤10 | 74 | 12 | 0.642 | 0.248 | 1 | 85 | 5.312 | 0.142 |
| >10 | 95 | 24 | (0.301-1.368) | 7 | 112 | (0.641-44.002) | ||
| Extrathyroidal invasion | ||||||||
| No | 87 | 24 | 1.885 | 0.097 | 1 | 110 | 8.851 | 0.025a |
| Yes | 82 | 12 | (0.885-4.014) | 7 | 87 | (1.069-73.300) | ||
| Multifocality | ||||||||
| Single | 85 | 24 | 1.976 | 0.074 | 1 | 108 | 8.494 | 0.027a |
| Multifocal | 84 | 12 | (0.928-4.208) | 7 | 89 | (1.026-70.344) | ||
| Lymph node metastasis | ||||||||
| No | 69 | 22 | 2.277 | 0.026a | 2 | 89 | 2.472 | 0.305 |
| Yes | 100 | 14 | (1.090-4.759) | 6 | 108 | (0.487-12.551) | ||
| TNM stage | ||||||||
| I–II | 100 | 23 | 1.221 | 0.600 | 1 | 122 | 11.387 | 0.007a |
| III–IV | 69 | 13 | (0.579-2.574) | 7 | 75 | (1.374-94.385) | ||
a
P<0.05. BRAF, B-Raf proto-oncogene; TERT, telomerase reverse transcriptase; OR, odds ratio; TNM, tumor/node/metastasis.